Our Technology

Innovative Chemistry
Transformative Therapies

FDA “Fast Track” and “Breakthrough Therapy” designations received. 

About us

What We Do

We’re a biotech company committed to stemming the prescription drug abuse epidemic.


Long Term

Events & Presentations

Ensysce Corporate Overview Find Out More

Events & Presentations

Special Meeting of Stockholders Find Out More

Events & Presentations

2022 Annual Meeting of Stockholders Find Out More
Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast Read More
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing Read More
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States Read More
Ensysce Biosciences Announces Enrolment Completion for PF614-201 Clinical Study Read More
Ensysce Biosciences Reports Third Quarter 2023 Financial Results Read More

Our Team

Brilliant minds
and vision

We’re proud to say our team is made up of just that — people and minds both driven by passion and full of potential. Our company is led by a team of executives and directors with vast experience and proven track records in pain, drug development and commercialization.

D. Lynn Kirkpatrick, PhD

Chief Executive Officer

Dave Humphrey

Chief Financial Officer

Bill Schmidt, PhD

Chief Medical Officer.

Jeffrey Millard, PhD

Chief Operating Officer

Geoff Birkett

Chief Commercial Officer

Linda Pestano, PhD

Chief Development Officer